Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBITDA (2017 - 2025)

Autolus Therapeutics' EBITDA history spans 6 years, with the latest figure at -$90.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 62.43% year-over-year to -$90.8 million; the TTM value through Dec 2025 reached -$263.7 million, down 19.41%, while the annual FY2025 figure was -$263.7 million, 19.41% down from the prior year.
  • EBITDA reached -$90.8 million in Q4 2025 per AUTL's latest filing, down from -$84.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$18.3 million in Q4 2022 to a low of -$90.8 million in Q4 2025.
  • Average EBITDA over 4 years is -$53.9 million, with a median of -$55.5 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 295.78% in 2023, then skyrocketed 49.43% in 2025.
  • A 4-year view of EBITDA shows it stood at -$18.3 million in 2022, then plummeted by 295.78% to -$72.4 million in 2023, then grew by 22.78% to -$55.9 million in 2024, then crashed by 62.43% to -$90.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's EBITDA are -$90.8 million (Q4 2025), -$84.9 million (Q3 2025), and -$28.9 million (Q2 2025).